ClinicalTrials.gg
CompletedNCT02549651Updated Feb 27, 2019

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

A Phase 1 interventional study of MEDI4736 and tremelimumab in Diffuse Large B-Cell Lymphoma, sponsored by MedImmune LLC. Completed at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-27.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca — 1 open to participants now, 3 under way, 1 of them phase 3. Lymphoma, Large B-Cell, Diffuse · AstraZeneca.

Enrollment
8th of 11
32 · median 67
Started
2016
with 1 other
Phase 1
6 of 12
none open now
Registered
5th of 12
by date

Among the 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2016, is one of 6 in phase 1, and was the 5th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

1 of the 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.

Read the detailed description

This is a multicenter, open-label, dose-escalation and dose-expansion study of MEDI4736 (durvalumab) as monotherapy or in combination with either tremelimumab or AZD9150. The objectives are to describe any dose-limiting toxicities, determine the maximum tolerated dose, and evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of MEDI4736 as monotherapy or in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma

Keywords

  • DLBCL
  • MEDI4736
  • durvalumab
  • tremelimumab
  • AZD9150
  • anti-PD-L1
  • anti-CTLA-4
  • immunotherapy
  • IMTC
  • STAT3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Subjects with confirmed DLBCL who have received at least 1 prior rituximab containing chemotherapy regimen but no more than 5
  3. Eastern Cooperative Group () performance status of 0 or 1
  4. by International Working Group (IWG) response criteria for lymphoma
  5. Adequate organ and marrow function

Exclusion criteria

Exclusion Criteria:

  1. Previous immune-mediated therapy
  2. Subjects with prior or allogenic HCT. Subjects ineligible for available curative options after failing ASCT and have met the hematologic criteria are eligible to participate in this study. Subjects with prior allogenic HCT will be excluded.
  3. Documented current central nervous system involvement
  1. Active or prior documented or inflammatory disease within 3 years, with some exceptions 4. Concurrent or prior conventional or anticancer therapy, within 28 days prior to the first dose of study medication(s)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    MEDI4736

    Drug: MEDI4736

  • Experimental
    MEDI4736 and tremelimumab

    Drug: MEDI4736 · Drug: tremelimumab

  • Experimental
    MEDI4736 and AZD9150

    Drug: MEDI4736 · Drug: AZD9150

Interventions

  • MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion

  • Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion

  • AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion

06

What researchers measure

Primary outcomes

  1. Number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events

    Time frame: Screening through 90 days after the last dose of study medication

  2. Number of subjects experiencing dose-limiting toxicities

    Changes from baseline in laboratory parameters, vital signs, and ECGs

    Time frame: First dose of study medications through 28 days after the administration of MEDI4736 or MEDI4736 and tremelimumab, 35 days after administration of MEDI4736 and AZD9150

Secondary outcomes

  1. Number of subjects who develop anti-drug antibodies (ADA)

    Time frame: Screening through 90 days after last dose of study medication

  2. Time to Response

    Time frame: Screening though 3 years after the last subject receives the first dose of study medication

  3. Duration of Response

    Time frame: Screening though 3 years after the last subject receives the first dose of study medication

  4. Progression Free survival

    Time frame: Screening though 3 years after the last subject receives the first dose of study medication

  5. Time to progression

    Time frame: Screening though 3 years after the last subject receives the first dose of study medication

  6. Event free survival

    Time frame: Screening though 3 years after the last subject receives the first dose of study medication

  7. Overall survival

    Time frame: Screening though 3 years after the last subject receives the first dose of study medication

  8. MEDI4736 Maximum Plasma Concentration (Cmax)

    Time frame: Measured at defined study visits from time of first dose through end of treatment

  9. Tremelimumab Maximum Plasma Concentration (Cmax)

    Time frame: Measured at defined study visits from time of first dose through end of treatment

  10. AZD9150 Maximum Plasma Concentration (Cmax)

    Time frame: Measured at defined study visits from time of first dose through end of treatment

  11. MEDI4736 Minimum Plasma Concentration (Cmin)

    Time frame: Measured at defined study visits from time of first dose through end of treatment

  12. Tremelimumab Minimum Plasma Concentration (Cmin)

    Time frame: Measured at defined study visits from time of first dose through end of treatment

  13. AZD9150 Minimum Plasma Concentration (Cmin)

    Time frame: Measured at defined study visits from time of first dose through end of treatment

  14. Individual MEDI4736 Concentrations

    Time frame: Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months)

  15. Individual tremelimumab Concentrations

    Time frame: Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months)

  16. Individual AZD9150 Concentrations

    Time frame: Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months)

  17. Change from baseline of STAT3 RNA (signal transducer and activator of transcription)

    Time frame: Measured at defined study visits from time of first dose through 90 days after last dose (approximately 15 months)

  18. Baseline PD-L1 protein expression within the tumor

    Time frame: Measured on tumor samples provided at screening

07

Study locations

13 sites
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Albuquerque, New Mexico 87131, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Dallas, Texas 75390, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Marseille, 13273, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Dublin 8, Ireland
  • Research Site
    Galway, Ireland
  • Research Site
    Leicester, LE1 5WW, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Feb 2019, 30 months.

Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 71. This study's 30 months is below that.

Counting every sponsor, half of 196 studies reached it within 55 months; a quarter within 36 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2015
First posted
Sep 15, 2015
StartActual
Jul 13, 2016
Primary completionActual
Feb 4, 2019
CompletionActual
Feb 4, 2019
Last update
Feb 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02549651
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Sep 15, 2015
Start date
Jul 13, 2016
Primary completion
Feb 4, 2019
Completion
Feb 4, 2019
Last update
Feb 27, 2019

Study contacts

MedImmune LLC
study director · MedImmune LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion